Home Tools
Log in
Cart

Tyrosine Kinases

A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell. It functions as an "on" or "off" switch in many cellular functions. Tyrosine kinases are a subclass of protein kinase.The phosphate group is attached to the amino acid tyrosine on the protein. Tyrosine kinases are a subgroup of the larger class of protein kinases that attach phosphate groups to other amino acids (serine and threonine). Phosphorylation of proteins by kinases is an important mechanism in communicating signals within a cell (signal transduction) and regulating cellular activity, such as cell division.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T6933 Peficitinib 944118-01-8 99.84%
Peficitinib
Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
T36584 HNMPA-(AM)3 120944-03-8 97.22%
HNMPA-(AM)3
HNMPA-(AM)3 inhibits activation of ERK phosphorylation and stimulation of ecdysteroid production by prothyrotropin (PTTH). Furthermore, HNMPA-(AM)3 had inhibitor...
T5049 NVP-BSK805 1092499-93-8
NVP-BSK805
NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.
T14669 BMS-066 914946-88-6 98%
BMS-066
BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.
T17184 Tyrosine kinase inhibitor 1021950-26-4 98%
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
T13233 Tyk2-IN-3 1779493-12-7 98%
Tyk2-IN-3
Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).
T6790 BMS-911543 1271022-90-2 99.98%
BMS-911543
BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.
T1936 Alectinib 1256580-46-7 99.97%
Alectinib
Alectinib (RG-7853) is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
T62447 Paltimatrectinib 2353522-15-1 99.96%
Paltimatrectinib
Paltimatrectinib (PBI-200) is a potent tyrosine kinase inhibitor with anticancer activity that inhibits myosin-related kinase A (TrkA).Paltimatrectinib is used i...
T3061 Lorlatinib 1454846-35-5 99.93%
Lorlatinib
Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1...
T1829 Ruxolitinib 941678-49-5 99.93%
Ruxolitinib
Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and ...
T15096 Delgocitinib 1263774-59-9 99.90%
Delgocitinib
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgoc...
T1917 GSK 3 Inhibitor IX 667463-62-9 99.9%
GSK 3 Inhibitor IX
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity w...
T13237L Ropsacitinib 2127109-84-4 99.85%
Ropsacitinib
Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).
T1835 Ibrutinib 936563-96-1 99.79%
Ibrutinib
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
T2485 Baricitinib 1187594-09-7 99.79%
Baricitinib
Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineopla...
T61494 JAK-IN-21 2445499-20-5 99.75%
JAK-IN-21
JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
T71857 GTP-14564 34823-86-4 99.69%
GTP-14564
GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3. GTP-14564 inhibits the growth of interleukin-3-independent Ba/F1 expressi...
T12266L Ilginatinib maleate 1354799-87-3 99.68%
Ilginatinib maleate
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.
T2360 Baricitinib phosphate 1187595-84-1 99.68%
Baricitinib phosphate
Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.
Peficitinib
T6933
Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
HNMPA-(AM)3
T36584
HNMPA-(AM)3 inhibits activation of ERK phosphorylation and stimulation of ecdysteroid production by prothyrotropin (PTTH). Furthermore, HNMPA-(AM)3 had inhibitor...
NVP-BSK805
T5049
NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.
BMS-066
T14669
BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.
Tyrosine kinase inhibitor
T17184
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
Tyk2-IN-3
T13233
Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).
BMS-911543
T6790
BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.
Alectinib
T1936
Alectinib (RG-7853) is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
Paltimatrectinib
T62447
Paltimatrectinib (PBI-200) is a potent tyrosine kinase inhibitor with anticancer activity that inhibits myosin-related kinase A (TrkA).Paltimatrectinib is used i...
Lorlatinib
T3061
Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1...
Ruxolitinib
T1829
Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and ...
Delgocitinib
T15096
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgoc...
GSK 3 Inhibitor IX
T1917
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity w...
Ropsacitinib
T13237L
Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).
Ibrutinib
T1835
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
Baricitinib
T2485
Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineopla...
JAK-IN-21
T61494
JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
GTP-14564
T71857
GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3. GTP-14564 inhibits the growth of interleukin-3-independent Ba/F1 expressi...
Ilginatinib maleate
T12266L
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.
Baricitinib phosphate
T2360
Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.
1 2 3
TargetMol